Division of Onxeo SA
Latest From Topotarget AS
Onxeo acquires signal-interfering DNA repair technology for its orphan oncology focus. Sanofi returns auto-injector product to kaleo after product recall.
Firm that was focused on technology to reformulate old drugs gains platform for novel drugs that will induce cell death in orphan oncology indications.
The year-old pan-European biotech is targeting advanced liver cancer, severe mucositis and the rare cancer, peripheral T-cell lymphoma, for its first products in the orphan oncology niche.
Pharma take a bow: in 2014 you launched a record number of new active substances in their first markets worldwide.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Onxeo SA
- Senior Management
Elisabeth V Carstensen, Dir., Pharmaceutical Operations
Inge Holm Lauritzen, VP, Bus. Dev. & Strategic Planning
- Contact Info
Phone: (45) 39 17 83 92
Symbion Science Park
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.